Autologous Bone Marrow-Derived Stem Cell Therapy in Combination with TMLR. A Novel Therapeutic Option for Endstage Coronary Heart Disease: Report on 2 Cases

Authors

  • H.-M. Klein
  • A. Ghodsizad
  • A. Borowski
  • A. Saleh
  • J. Draganov
  • L. Poll
  • V. Stoldt
  • N. Feifel
  • C. Piecharczek
  • E.R. Burchardt
  • M. Stockschläder
  • E. Gams

DOI:

https://doi.org/10.1532/HSF98.20041095

Abstract

We report 2 cases in which patients with coronary heart disease not amenable for conventional revascularization underwent transmyocardial laser revascularization (TMLR) and implantation of AC133+ bone-marrow stem cells. The reason for using TMLR in combination with stem cell application is to take advantage of the synergistic angiogenic effect. The local inflammatory reaction induced by TMLR should serve as an informational platform for stem cells and may trigger their angiogenic differentiation. Functional analysis of myocardial performance after treatment in these 2 cases revealed dramatic improvement of the wall motion at the site of the TMLR and stem cell application. Because TMLR does not enhance myocardial contractility and there was no angiographic evidence of major collaterals to the ischemic region in either patient, we assume that the synergistic effect of stem cells and TMLR-induced angiogenesis occurred; however, our assumption is of a speculative nature. We think that TMLR in combination with stem cell transplantation might become a novel revascularization therapy for ischemic myocardium.

References

Frazier OH, March RJ, Hovarth KA, et al. 1999. Transmyocardial revascularization with a carbon dioxide laser in patients with end-stage coronary artery disease. New Engl J Med 341:1021-8.nHakuno D, Fukuda K, Makino S, et al. 1999. Bone marrow-derived regenerated cardiomyocytes (CMG lines) express functional adrenergic and muscarinic receptors. Circulation 100:II247-56.nHeilmann CA, Attmann T, Lutter G, et al. 2003. Transmyocardial laser revascularisation combined with vascular endothelial growth factor 121 (VEGF 121) gene therapy for chronic myocardial ischemia--do the effects really add up. Eur J Cardiothoracic Surg 23(1):74-80.nKarabatsch T, Schäper F, Hetzer R, et al. 1996. Histological findings after transmyocardial laser re-vascularisation. J Card Surgery 11:326-31.nKocher AA, Schuster MD, Wang, et al. 2001. Neovascularisation of ischemic myocardium by human bone marrow derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 7:430-6.nLutter G, Attmann T, Beyersdorf F, et al. 2002. The combined use of transmyocardial laser revascularisation and FGF-2 enhances perfusion and regional contractility in chronically ischemic porcine hearts. Eur J Cardiothoracic Surg 22:753-61.nMenasche P, Hagege AA, Scorsin, et al. 2001. Myoblast transplantation for heart failure. Lancet 357:279-80.nOrlic D, Kajstura J, Anversa P, et al. 2001. Bone marrow cells regenerate infarcted myocardium. Nature 410(6829):701-5.nPesce M, Orlandi A, Capogrossi MC, et al. 2003. Myoendothelial differentiation of human umbilical cord blood-derived stem cells in ischemic limb tissues. Circ Res 93(5):e51-62. Epub 2003 Aug 14.nQuirici N, Soligo D, Deliliers GL, et al. 2001. Differentiation and expansion of endothelial cells from human bone marrow CD133(+) cells. Br J Haematol 115(1):186-94.nSchneider J, Diegeler, Mohr FW, et al. 2001. Transmyocardial laser revascularisation with holmium: YAG-Laser: loss of symptomatic improvement after 2 years. Eur J Cardiothoracic Surg 19(2):164-9.nStamm C, Westphal B, Steinhoff G, et al. 2003. Autologous bone-marrow stem-cell transplantation for myocardial regeneration. Lancet 361(9351):45-6.nStrauer BE, Brehm M, Wernet P, et al. 2002. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation 106:1913-8.nAllen KB, Dowling RD, O'Neill WW, et al. 1999. Comparison of transmyocardial revascularization with medical therapy in patients with refractory angina. New Engl J Med 1999; 341:1029-36.nWilke NM, Zenovich A, Muehling O, Jerosch-Herold M. 2000. Novel revascularisation therapies--TMLR and growth factor induced angiogenesis monitored with cardiac MRI. MAGMA 11(1-2):61-4.nn

Published

2005-01-04

How to Cite

Klein, H.-M., Ghodsizad, A., Borowski, A., Saleh, A., Draganov, J., Poll, L., Stoldt, V., Feifel, N., Piecharczek, C., Burchardt, E., Stockschläder, M., & Gams, E. (2005). Autologous Bone Marrow-Derived Stem Cell Therapy in Combination with TMLR. A Novel Therapeutic Option for Endstage Coronary Heart Disease: Report on 2 Cases. The Heart Surgery Forum, 7(5), E416-E419. https://doi.org/10.1532/HSF98.20041095

Issue

Section

Article